TY  - JOUR
AU  - Gaibar, María
AU  - Novillo, Apolonia
AU  - Romero-Lorca, Alicia
AU  - Malón, Diego
AU  - Antón, Beatriz
AU  - Moreno, Amalia
AU  - Fernández-Santander, Ana
AU  - Novillo Villajos, Apolonia
PY  - 2022
DO  - 10.3390/pharmaceutics14020242
SN  - 1999-4923
UR  - https://hdl.handle.net/20.500.14352/130317
T2  - Phramaceutics
AB  - HER2-positive breast cancer (BC) is an aggressive subtype that affects 20–25% of BC patients. For these patients, neoadjuvant therapy is a good option that targets a pathological complete response (pCR) and more breast-conserving surgery. In effect,...
LA  - eng
M2  - 242
PB  - MPDI
KW  - CNVs
KW  - FGFR1 gene
KW  - HER2-positive breast cancer
KW  - Miller–Payne grading
KW  - Anti-HER2 treatment
KW  - Pathological complete response
TI  - FGFR1 Amplification and Response to Neoadjuvant Anti-HER2 Treatment in Early HER2-Positive Breast Cancer
TY  - journal article
VL  - 14
ER  -